Share Price, page-15429

Yes it is very frustrating. I will hold for a bit longer as I do feel with the right tailwind from the US markets we might break through. This is what Stock Analysis GPT has to say on the matter...

Why NEU Is Heavily Shorted

1. Valuation vs. Fundamentals (Biotech Premium)

• NEU trades with a biotech premium due to its commercialisation prospects (e.g., trofinetide for Rett Syndrome).

• Short sellers may believe the valuation has run ahead of clinical or commercial reality—pricing in too much success too early.

2. Illiquidity and Small Float

• With a smaller public float and lower average daily volume, it’s easier for short sellers to suppress upward momentum, particularly near psychological barriers like $13.00.

• This allows for tactical “short wall” defense, where selling pressure at key levels repeatedly turns back rallies.

3. Technical Rejection at $13

• As you mentioned, every move above $13 gets rejected—this likely isn’t random.

• $13 has become a battleground, possibly due to short positions being built or defended there.

• Algorithmic short-sellers often park offers just above recent highs to maintain price caps.

4. Lack of Major Catalyst Near Term

• Short sellers thrive on no-news periods. NEU is in a commercial stage, but no major catalysts (like FDA approvals or earnings beats) are expected short-term.

• Without news, it's easier to fade rallies and shake out weak longs.

5. General Sentiment Shift Against Biotech

• The global biotech sector has underperformed in recent quarters amid rising rates and risk-off sentiment.

• This makes high-beta names like NEU prime candidates for sector-based shorting strategies.

Implications of 6.3% Short Interest

	Short Interest Level	Implication
1	>5%	Institutions are actively shorting
2	~6.3% (NEU now)	High enough to pressure price; potential for short squeeze if catalyst emerges
3	<2%	Typically “neutral”

Strategic Insight

• The presence of a visible ceiling at $13 likely reflects algorithmic and institutional defense of short positions.

• However, if NEU breaks cleanly above $13.10–13.20 on volume, shorts could be forced to cover aggressively, setting up a short squeeze.

• Combine this with the accumulation signs you're seeing around $12.75–12.85, and you have a setup that could go either way—but the pressure is building.

Would you like a chart overlay to show how often NEU is rejected near $13 or help design a trading strategy to play a short squeeze breakout?

4o

You said:

yes please show a chart overlay to show how often NEU is rejected near $13

Here's the chart showing NEU’s daily highs over the past 30 trading sessions with a clear red dashed line at $13.00. You can see how frequently the stock has approached or slightly exceeded $13, only to be rejected soon after. This visual pattern supports the observation that $13 is acting as a strong resistance level — a typical target for short sellers looking to suppress upward momentum.

This kind of repeated rejection is often symptomatic of:

• Heavy short interest near round-number resistance.

• Algorithmic resistance defense, where large sell orders trigger just above $13.

• Psychological resistance, as traders anticipate pullbacks there.

Let me know if you’d like a version overlaid with volume data or trade volumes near $13.